Structure Therapeutics (GPCR) CSO has 18,735 shares withheld for taxes

Rhea-AI Filing Summary

Structure Therapeutics Inc. chief scientific officer Xichen Lin reported a routine tax-related share transaction. On March 3, 2026, Lin had 18,735 Ordinary Shares withheld at $20.99 per share to cover income taxes triggered by the vesting of a restricted share unit award.

After this tax-withholding disposition, Lin directly owned 185,592 Ordinary Shares. The company notes that each American Depositary Share (ADS) represents three Ordinary Shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Xichen

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		F		18,735(2)	D	$20.99	185,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

	/s/ Jun Yoon, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Structure Therapeutics (GPCR) report for Xichen Lin?

Structure Therapeutics reported that chief scientific officer Xichen Lin had shares withheld to cover taxes. On March 3, 2026, the company withheld 18,735 Ordinary Shares as part of income tax obligations tied to the vesting of a restricted share unit award.

Was the GPCR Form 4 transaction a sale by Xichen Lin on the open market?

The Form 4 describes a tax-withholding disposition, not an open-market sale. 18,735 Ordinary Shares were withheld by the issuer to satisfy income tax obligations upon RSU vesting, rather than being sold at the officer’s discretion in the market.

How many Structure Therapeutics shares does Xichen Lin own after this Form 4?

Following the tax-withholding transaction, Xichen Lin directly owned 185,592 Ordinary Shares of Structure Therapeutics. This figure represents Lin’s reported direct ownership after the issuer withheld 18,735 shares to cover income tax liabilities from RSU vesting.

At what price were the withheld Structure Therapeutics (GPCR) shares valued?

The withheld shares were valued at $20.99 per Ordinary Share. This price was used to calculate the tax-withholding disposition of 18,735 Ordinary Shares related to the vesting of a restricted share unit award for chief scientific officer Xichen Lin.

How are Structure Therapeutics Ordinary Shares related to its ADSs?

Structure Therapeutics states that its Ordinary Shares may be represented by American Depositary Shares. Each ADS represents three Ordinary Shares, providing investors with a depositary receipt structure while maintaining a clear conversion ratio between ADSs and the underlying Ordinary Shares.

What does transaction code F mean in the Structure Therapeutics Form 4?

Transaction code F indicates payment of an exercise price or tax liability by delivering securities. In this case, 18,735 Ordinary Shares were withheld by Structure Therapeutics to satisfy chief scientific officer Xichen Lin’s income tax obligations from a restricted share unit vesting.